Clinical Trial Update: Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating XC221 for efficacy and safety in influenza and acute respiratory viral infections completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• XC221

Snippet

Sponsor: PHARMENTERPRISES LLC | Conditions: Acute Respiratory Viral Infections, Influenza | Phase 2 | Status: COMPLETED | Results posted: 2019-11-04